Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: -$1.90 vs -$2.35 estimate, beat.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-30Revenue: $198MGross profit: $197M; Gross margin: 99.8%Operating income: -$373MNet income: -$407M; GAAP diluted EPS: -$1.90Operating cash flow: -$416M; Capex: $4M; Free cash flow: -$419MCash: $616M; Total debt: $639M; Net debt: $23MOfficial release: Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
核心结果
实际值与市场预期
EPS：-$1.90 vs -$2.35 预期，高于预期。财务指标
期间：2026 Q3（截至 2026-09-30）营收：$198M毛利润：$197M；毛利率：99.8%经营利润：-$373M净利润：-$407M；GAAP 稀释 EPS：-$1.90经营现金流：-$416M；资本开支：$4M；自由现金流：-$419M现金：$616M；总债务：$639M；净债务：$23M
